



(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 413/04 (2006.01)
C07D 413/14 (2006.01) A61K 31/5377 (2006.01)
C07D 213/74 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2015/056986

(22) International Filing Date:

11 September 2015 (11.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/049,469 12 September 2014 (12.09.2014) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [—/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **BURGER, Matthew T.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **RAMURTHY, Savithri** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TAFT, Benjamin R.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Bldg. #4, Emeryville, Massachusetts 94608 (US).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AF, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BI, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GI, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS



(57) Abstract: The present invention provides a compound of Formula (I), wherein X, Y, Z, R₁ and R₂ are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.